We are live on ! Find out more
SL

Siren LLC Portfolio holdings

AUM $3.61B
1-Year Est. Return 203.3%
This Fund
S&P 500
This Quarter Est. Return
+28.71%
1 Year Est. Return
+203.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.61B
AUM Growth
+$255M
Cap. Flow
+$47.3M
Cap. Flow %
1.31%
Top 10 Hldgs %
49.77%
Holding
131
New
18
Increased
36
Reduced
18
Closed
31

Top Buys

Rank Stock Value
1
MANE
Veradermics Inc
MANE
+$75.9M
2
CYTK icon
Cytokinetics
CYTK
+$39M
3
OLMA icon
Olema Pharmaceuticals
OLMA
+$32.4M
4
ERAS icon
Erasca
ERAS
+$29.4M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$23.3M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$76.1M
2
APLS
Apellis Pharmaceuticals
APLS
+$64.8M
3
ASND icon
Ascendis Pharma A/S
ASND
+$50.3M
4
RAPT
RAPT Therapeutics
RAPT
+$46.6M
5
ZYME icon
Zymeworks
ZYME
+$44.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.63%
2 Technology 3.69%
3 Communication Services 1.71%
4 Consumer Discretionary 0.77%
5 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
26
Dyne Therapeutics
DYN
$4.24B
$40.4M 1.12%
2,229,125
-1,273,816
-36% -$22M
TSHA icon
27
Taysha Gene Therapies
TSHA
$1.59B
$39.5M 1.09%
8,829,913
-1,300,000
-13% -$6.04M
DBVT
28
DBV Technologies
DBVT
$823M
$38.8M 1.08%
1,857,362
– –
ORIC icon
29
Oric Pharmaceuticals
ORIC
$1.24B
$38M 1.05%
2,998,192
+1,990,617
+198% +$22.6M
ENGN icon
30
enGene Therapeutics
ENGN
$118M
$35.8M 0.99%
5,253,159
+1,916,895
+57% +$17.1M
PVLA
31
Palvella Therapeutics
PVLA
$2.03B
$32.1M 0.89%
257,485
+182,485
+243% +$19M
TBLA icon
32
Taboola.com
TBLA
$1.35B
$30.9M 0.86%
9,969,495
– –
ELVN icon
33
Enliven Therapeutics
ELVN
$3.77B
$29.3M 0.81%
+746,226
New +$20.7M
DNLI icon
34
Denali Therapeutics
DNLI
$3.74B
$26.8M 0.74%
1,396,513
– –
RELY icon
35
Remitly
RELY
$4.77B
$24.2M 0.67%
1,543,271
-75,000
-5% -$1.11M
DMRA
36
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.81B
$23.3M 0.65%
+900,000
New +$23.1M
ZURA icon
37
Zura Bio
ZURA
$511M
$22.2M 0.62%
3,734,866
+2,434,866
+187% +$14.7M
ANNX icon
38
Annexon
ANNX
$841M
$21.9M 0.61%
+3,958,646
New +$22.3M
TRVI icon
39
Trevi Therapeutics
TRVI
$2.57B
$21.3M 0.59%
1,786,867
-500,000
-22% -$5.6M
RAPP
40
Rapport Therapeutics
RAPP
$2.01B
$20.1M 0.56%
641,469
-67,000
-9% -$1.88M
GOOGL icon
41
Alphabet (Google) Class A
GOOGL
$3.99T
$18.9M 0.52%
65,703
+45,000
+217% +$14.1M
FULC icon
42
Fulcrum Therapeutics
FULC
$249M
$18M 0.5%
2,350,000
+400,000
+21% +$3.71M
WVE icon
43
Wave Life Sciences
WVE
$1.14B
$17.8M 0.49%
2,450,000
– –
DFTX
44
Definium Therapeutics
DFTX
$5.66B
$17.4M 0.48%
919,493
+119,493
+15% +$2.03M
AMLX icon
45
Amylyx Pharmaceuticals
AMLX
$2.17B
$17.1M 0.47%
+1,230,000
New +$17.3M
CGEM icon
46
Cullinan Oncology
CGEM
$1.07B
$17M 0.47%
1,193,410
– –
NMRA icon
47
Neumora Therapeutics
NMRA
$308M
$16.6M 0.46%
8,497,822
+2,209,039
+35% +$5.72M
QURE icon
48
uniQure
QURE
$2.63B
$16.4M 0.45%
+1,000,000
New +$20.2M
CTMX icon
49
CytomX Therapeutics
CTMX
$708M
$16.3M 0.45%
+3,457,711
New +$17.6M
NVDA icon
50
NVIDIA
NVDA
$4.76T
$15.5M 0.43%
89,085
+51,600
+138% +$9.47M
1
2
3 4 5

Similar funds

U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
WB
WesBanco Bank Wheeling, West Virginia $3.61B AUM 24.09% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $3.63B AUM 17.91% 1-Year Est. Return

Siren LLC's Q1 2026 Portfolio in Review

As of Q1 2026, Siren LLC held 131 positions worth $3.61B, up 7.6% from $3.35B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Siren LLC's Q1 2026 filing shows 18 new, 36 increased, 18 reduced and 31 closed positions. Its largest new stake was Veradermics Inc: 1,505,374 shares worth $95.1M. The largest sale was Centessa Pharmaceuticals, an estimated $76.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Technology and Communication Services.

  • Siren LLC's largest Q1 2026 buy was Veradermics Inc: 1,505,374 shares worth $95.1M.
  • Siren LLC added most to Olema Pharmaceuticals in Q1 2026, an estimated $32.4M increase.
  • Siren LLC's biggest Q1 2026 reduction was Centessa Pharmaceuticals, cutting an estimated $76.1M.
  • Siren LLC fully exited Apellis Pharmaceuticals in Q1 2026, selling an estimated $64.8M.
  • Siren LLC's ten largest holdings make up 50% of its $3.61B portfolio in Q1 2026.
  • Siren LLC opened 18 new positions and closed 31 in Q1 2026.
  • Siren LLC's portfolio value rose 7.6% quarter-over-quarter to $3.61B.

Based on Siren LLC's 13F filing for Q1 2026, filed 14 May 2026.